KR102769578B1 - 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료 - Google Patents

산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료 Download PDF

Info

Publication number
KR102769578B1
KR102769578B1 KR1020207008213A KR20207008213A KR102769578B1 KR 102769578 B1 KR102769578 B1 KR 102769578B1 KR 1020207008213 A KR1020207008213 A KR 1020207008213A KR 20207008213 A KR20207008213 A KR 20207008213A KR 102769578 B1 KR102769578 B1 KR 102769578B1
Authority
KR
South Korea
Prior art keywords
patient
pharmaceutical composition
leu
acid sphingomyelinase
bone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207008213A
Other languages
English (en)
Korean (ko)
Other versions
KR20200044064A (ko
Inventor
아나 크리스티나 샤이트-푸가
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Priority to KR1020257004704A priority Critical patent/KR20250025051A/ko
Publication of KR20200044064A publication Critical patent/KR20200044064A/ko
Application granted granted Critical
Publication of KR102769578B1 publication Critical patent/KR102769578B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020207008213A 2017-08-24 2018-08-22 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료 Active KR102769578B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257004704A KR20250025051A (ko) 2017-08-24 2018-08-22 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762549732P 2017-08-24 2017-08-24
US62/549,732 2017-08-24
EP17306720.8 2017-12-07
EP17306720 2017-12-07
PCT/IB2018/056346 WO2019038685A2 (en) 2017-08-24 2018-08-22 TREATMENT OF ABNORMAL BONE CONDITIONS IN PATIENTS WITH ACIDIC SPHINGOMYELASE DISEASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257004704A Division KR20250025051A (ko) 2017-08-24 2018-08-22 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료

Publications (2)

Publication Number Publication Date
KR20200044064A KR20200044064A (ko) 2020-04-28
KR102769578B1 true KR102769578B1 (ko) 2025-02-20

Family

ID=63556374

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207008213A Active KR102769578B1 (ko) 2017-08-24 2018-08-22 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료
KR1020257004704A Pending KR20250025051A (ko) 2017-08-24 2018-08-22 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257004704A Pending KR20250025051A (ko) 2017-08-24 2018-08-22 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료

Country Status (17)

Country Link
US (2) US11898175B2 (enExample)
EP (1) EP3672622B1 (enExample)
JP (3) JP7216075B2 (enExample)
KR (2) KR102769578B1 (enExample)
CN (2) CN111344003B (enExample)
AU (2) AU2018319565B2 (enExample)
BR (1) BR112020003541A2 (enExample)
CA (1) CA3073648A1 (enExample)
CO (1) CO2020001801A2 (enExample)
ES (1) ES2970423T3 (enExample)
IL (1) IL272757B2 (enExample)
MX (2) MX2020002106A (enExample)
NZ (1) NZ762860A (enExample)
PL (1) PL3672622T3 (enExample)
SG (1) SG11202001544VA (enExample)
TW (1) TWI791040B (enExample)
WO (1) WO2019038685A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392330B (es) * 2009-08-28 2025-03-11 Icahn School Med Mount Sinai Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonado de la dosis para tratar la deficiencia de esfingomielinasa ácida.
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
JP7568648B2 (ja) * 2019-05-31 2024-10-16 ジェンザイム・コーポレーション 二次元ｌｃ－ｍｓ／ｍｓシステム
CN112773779B (zh) * 2021-02-04 2022-08-16 上海交通大学医学院附属新华医院 氨溴索、千金藤和汉防已在治疗酸性鞘磷脂酶缺乏症中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
CN1302897A (zh) 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
EP1901770B1 (en) * 2005-06-02 2014-12-24 Ipsen Biopharmaceuticals, Inc. Gh and igf-1 for treatment of growth disorders
MX392330B (es) * 2009-08-28 2025-03-11 Icahn School Med Mount Sinai Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonado de la dosis para tratar la deficiencia de esfingomielinasa ácida.
CA2865614A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
HK1216007A1 (zh) 2012-12-12 2016-10-07 Teva Pharmaceutical Industries Ltd. 人体生长激素和白蛋白的融合、制剂及其用途
SI3004896T1 (sl) 2013-06-07 2020-01-31 Genzyme Corporation Označevalec za motnje kisle sfingomielinaze in njegova uporaba

Also Published As

Publication number Publication date
AU2025203384A1 (en) 2025-05-29
US20210139868A1 (en) 2021-05-13
JP7431356B2 (ja) 2024-02-14
EP3672622B1 (en) 2023-11-08
CN111344003A (zh) 2020-06-26
NZ762860A (en) 2025-09-26
JP2024050732A (ja) 2024-04-10
CO2020001801A2 (es) 2020-04-01
TW201919689A (zh) 2019-06-01
KR20200044064A (ko) 2020-04-28
IL272757A (en) 2020-04-30
AU2018319565B2 (en) 2025-02-20
SG11202001544VA (en) 2020-03-30
MX2023010908A (es) 2023-09-27
WO2019038685A2 (en) 2019-02-28
ES2970423T3 (es) 2024-05-28
IL272757B1 (en) 2024-03-01
JP2023052459A (ja) 2023-04-11
CA3073648A1 (en) 2019-02-28
EP3672622A2 (en) 2020-07-01
AU2018319565A1 (en) 2020-04-09
MX2020002106A (es) 2020-07-14
JP2020531527A (ja) 2020-11-05
RU2020111649A (ru) 2021-09-24
US20240218338A1 (en) 2024-07-04
BR112020003541A2 (pt) 2020-09-01
KR20250025051A (ko) 2025-02-20
CN111344003B (zh) 2024-05-07
PL3672622T3 (pl) 2024-04-02
WO2019038685A3 (en) 2019-05-02
JP7216075B2 (ja) 2023-01-31
TWI791040B (zh) 2023-02-01
US11898175B2 (en) 2024-02-13
IL272757B2 (en) 2024-07-01
CN118453843A (zh) 2024-08-09

Similar Documents

Publication Publication Date Title
JP7431356B2 (ja) 酸性スフィンゴミエリナーゼ欠損症患者における骨状態異常の処置
KR102094253B1 (ko) 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
Pogoryelova et al. GNE myopathy: from clinics and genetics to pathology and research strategies
Marcucci et al. Gaucher disease and bone manifestations
Scott Asfotase alfa: a review in paediatric-onset hypophosphatasia
Hashemieh et al. Prevalence of osteoporosis among thalassemia patients from Zafar adult thalassemia clinic, Iran
Andiran et al. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation
Wesolek et al. Assessment of progranulin and FAM19A5 protein blood levels in patients with metabolic syndrome
RU2795570C2 (ru) Лечение патологических состояний кости у пациентов с дефицитом кислой сфингомиелиназы
EP4291224A1 (en) Alkaline phosphatase polypeptides and methods of use thereof
Elkin Arthritis, vasculitis and bone disease
Li et al. rhCygb benefits bleomycin-induced established pulmonary fibrosis in rats

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1102 Extension of patent period due to registration delay

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 39

St.27 status event code: A-4-4-G10-G17-tad-PR1102